---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037038"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:47:37.537506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q3 net loss narrows to $41.9M; APONVIE approved, launch Q1 2023

## Summary
- Net product sales $26.6M (+15% YoY); net loss $41.9M vs $52.4M YoY; oncology franchise sales $23.9M (+13%).
- ZYNRELEF unit demand grew 18% QoQ; Q4 net sales expected to rise 30-40% QoQ.
- APONVIE (aprepitant) FDA approved Sep 16; U.S. launch planned Q1 2023.
- Completed $75M private placement to strengthen balance sheet; cash $121.7M.
- Full-year 2022 oncology care franchise guidance reaffirmed at $93-95M.

## SEC filing metadata
- accession: 0001564590-22-037038
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/0001564590-22-037038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/hrtx-8k_20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037038
- JSON: https://secwatch.observer/filing/0001564590-22-037038.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037038.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ reported three and nine months ended September 30, 2022 results: revenue $26.6 million and $77.6 million, net income $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share. Guidance reaffirmed.
  - Period: three and nine months ended September 30, 2022
  - Revenue: $26.6 million and $77.6 million
  - Net income: $41.9 million, or $0.38 per share, and $162.2 million, or $1.54 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: franchises and extend our runway against a challenging external backdrop.” Financial Results Net product sales for the three and nine months ended September 30, 2022 were $26.6 million and $77.6 million, respectively, compared to $23.2 million and $65.7 million, respectively, for the same periods in 2021. Heron’s net loss for the three and nine months ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000156459022037038/0001564590-22-037038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.